1
|
Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X, Uchio Y, Kubo M, Kamatani Y, Lophatananon A, Wan P, Andrews C, Lori A, Choudhury PP, Schleutker J, Tammela TL, Sipeky C, Auvinen A, Giles GG, Southey MC, MacInnis RJ, Cybulski C, Wokolorczyk D, Lubinski J, Rentsch CT, Cho K, Mcmahon BH, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nordestgaard BG, Nielsen SF, Weischer M, Bojesen SE, Røder A, Stroomberg HV, Batra J, Chambers S, Horvath L, Clements JA, Tilly W, Risbridger GP, Gronberg H, Aly M, Szulkin R, Eklund M, Nordstrom T, Pashayan N, Dunning AM, Ghoussaini M, Travis RC, Key TJ, Riboli E, Park JY, Sellers TA, Lin HY, Albanes D, Weinstein S, Cook MB, Mucci LA, Giovannucci E, Lindstrom S, Kraft P, Hunter DJ, Penney KL, Turman C, Tangen CM, Goodman PJ, Thompson IM, Hamilton RJ, Fleshner NE, Finelli A, Parent MÉ, Stanford JL, Ostrander EA, Koutros S, Beane Freeman LE, Stampfer M, Wolk A, Håkansson N, Andriole GL, Hoover RN, Machiela MJ, Sørensen KD, Borre M, Blot WJ, Zheng W, Yeboah ED, Mensah JE, Lu YJ, Zhang HW, Feng N, Mao X, Wu Y, Zhao SC, Sun Z, Thibodeau SN, McDonnell SK, Schaid DJ, West CM, Barnett G, Maier C, Schnoeller T, Luedeke M, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Koudou YA, John EM, Grindedal EM, Maehle L, Khaw KT, Ingles SA, Stern MC, Vega A, Gómez-Caamaño A, Fachal L, Rosenstein BS, Kerns SL, Ostrer H, Teixeira MR, Paulo P, Brandão A, Watya S, Lubwama A, Bensen JT, Butler EN, Mohler JL, Taylor JA, Kogevinas M, Dierssen-Sotos T, Castaño-Vinyals G, Cannon-Albright L, Teerlink CC, Huff CD, Pilie P, Yu Y, Bohlender RJ, Gu J, Strom SS, Multigner L, Blanchet P, Brureau L, Kaneva R, Slavov C, Mitev V, Leach RJ, Brenner H, Chen X, Holleczek B, Schöttker B, Klein EA, Hsing AW, Kittles RA, Murphy AB, Logothetis CJ, Kim J, Neuhausen SL, Steele L, Ding YC, Isaacs WB, Nemesure B, Hennis AJ, Carpten J, Pandha H, Michael A, Ruyck KD, Meerleer GD, Ost P, Xu J, Razack A, Lim J, Teo SH, Newcomb LF, Lin DW, Fowke JH, Neslund-Dudas CM, Rybicki BA, Gamulin M, Lessel D, Kulis T, Usmani N, Abraham A, Singhal S, Parliament M, Claessens F, Joniau S, den Broeck TV, Gago-Dominguez M, Castelao JE, Martinez ME, Larkin S, Townsend PA, Aukim-Hastie C, Bush WS, Aldrich MC, Crawford DC, Srivastava S, Cullen J, Petrovics G, Casey G, Wang Y, Tettey Y, Lachance J, Tang W, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Yamoah K, Govindasami K, Chokkalingam AP, Keaton JM, Hellwege JN, Clark PE, Jalloh M, Gueye SM, Niang L, Ogunbiyi O, Shittu O, Amodu O, Adebiyi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Diop H, Gundell SM, Roobol MJ, Jenster G, van Schaik RH, Hu JJ, Sanderson M, Kachuri L, Varma R, McKean-Cowdin R, Torres M, Preuss MH, Loos RJ, Zawistowski M, Zöllner S, Lu Z, Van Den Eeden SK, Easton DF, Ambs S, Edwards TL, Mägi R, Rebbeck TR, Fritsche L, Chanock SJ, Berndt SI, Wiklund F, Nakagawa H, Witte JS, Gaziano JM, Justice AC, Mancuso N, Terao C, Eeles RA, Kote-Jarai Z, Madduri RK, Conti DV, Haiman CA. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet 2023; 55:2065-2074. [PMID: 37945903 PMCID: PMC10841479 DOI: 10.1038/s41588-023-01534-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2022] [Accepted: 09/15/2023] [Indexed: 11/12/2023]
Abstract
The transferability and clinical value of genetic risk scores (GRSs) across populations remain limited due to an imbalance in genetic studies across ancestrally diverse populations. Here we conducted a multi-ancestry genome-wide association study of 156,319 prostate cancer cases and 788,443 controls of European, African, Asian and Hispanic men, reflecting a 57% increase in the number of non-European cases over previous prostate cancer genome-wide association studies. We identified 187 novel risk variants for prostate cancer, increasing the total number of risk variants to 451. An externally replicated multi-ancestry GRS was associated with risk that ranged from 1.8 (per standard deviation) in African ancestry men to 2.2 in European ancestry men. The GRS was associated with a greater risk of aggressive versus non-aggressive disease in men of African ancestry (P = 0.03). Our study presents novel prostate cancer susceptibility loci and a GRS with effective risk stratification across ancestry groups.
Collapse
Affiliation(s)
- Anqi Wang
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Jiayi Shen
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | | | | | - Fei Chen
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Rohini Janivara
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
| | - Burcu F. Darst
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Xin Sheng
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Yili Xu
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Alisha J. Chou
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Sara Benlloch
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology,University of Cambridge, Cambridge, UK
| | | | | | - Anna Plym
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
- Urology Division, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
| | - Ali Sahimi
- Department of Population and Public Health Sciences, Keck School of Medicine,University of Southern California, Los Angeles, CA, USA
| | - Thomas J. Hoffman
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA
- Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA
| | - Atushi Takahashi
- Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
- Department of Genomic Medicine, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan
| | - Koichi Matsuda
- Department of Computational Biology and Medical Sciences, Laboratory of Clinical Genome Sequencing,Graduate school of Frontier Sciences,The University of Tokyo, Tokyo, Japan
| | - Yukihide Momozawa
- Laboratory for Genotyping Development, RIKEN Center of Integrative Medical Sciences, Yokohama, Japan
| | - Masashi Fujita
- Laboratory for Cancer Genomics, RIKEN Center of Integrative Medical Sciences, Yokohama, Japan
| | - Triin Laisk
- Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
| | - Jéssica Figuerêdo
- Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
| | - Kenneth Muir
- Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
- Warwick Medical School, University of Warwick, Coventry, UK
| | - Shuji Ito
- Department of Orthopaedics, Shimane University, Izumo, Shimane, Japan
- RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Xiaoxi Liu
- Laboratory for Statistical and Translational Genetics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
| | - The Biobank Japan Project
- Corresponding Author: Christopher A. Haiman, Harlyne J. Norris Cancer Research Tower, USC Norris Comprehensive Cancer Center, 1450 Biggy Street, Rm 1504, Los Angeles, CA 90033 or
| | - Yuji Uchio
- Department of Orthopaedics, Shimane University, Izumo, Shimane, Japan
| | - Michiaki Kubo
- RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Yoichiro Kamatani
- Laboratory for Statistical and Translational Genetics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
- Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
| | - Artitaya Lophatananon
- Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester, UK
| | - Peggy Wan
- Department of Population and Public Health Sciences, Keck School of Medicine,University of Southern California, Los Angeles, CA, USA
| | - Caroline Andrews
- Harvard TH Chan School of Public Health and Division of Population Sciences,Dana Farber Cancer Institute, Boston, MA, USA
| | - Adriana Lori
- Department of Population Science, American Cancer Society, Kennesaw, GA, USA
| | | | - Johanna Schleutker
- Institute of Biomedicine, University of Turku, Turku, Finland
- Department of Medical Genetics, Genomics, Laboratory Division, Turku University Hospital, Turku, Finland
| | | | - Csilla Sipeky
- Institute of Biomedicine, University of Turku, Turku, Finland
| | - Anssi Auvinen
- Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland
| | - Graham G. Giles
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health,The University of Melbourne, Victoria, Australia
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
| | - Melissa C. Southey
- Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
| | - Robert J. MacInnis
- Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health,The University of Melbourne, Victoria, Australia
| | - Cezary Cybulski
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Dominika Wokolorczyk
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Jan Lubinski
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Christopher T. Rentsch
- Yale School of Medicine, New Haven, CT, USA
- Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK
- VA Connecticut Healthcare System, West Haven, CT, USA
| | - Kelly Cho
- Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- VA Boston Healthcare System, Boston, MA, USA
| | | | - David E. Neal
- Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK
- University of Cambridge, Department of Oncology, Addenbrooke’s Hospital, Cambridge, UK
- Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge, UK
| | - Jenny L. Donovan
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
| | - Freddie C. Hamdy
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
- Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford, UK
| | - Richard M. Martin
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- NIHR Bristol Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, Bristol, UK
- Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol, UK
| | - Borge G. Nordestgaard
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Copenhagen, Denmark
| | - Sune F. Nielsen
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Copenhagen, Denmark
| | - Maren Weischer
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Copenhagen, Denmark
| | - Stig E. Bojesen
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Copenhagen, Denmark
| | - Andreas Røder
- Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Hein V. Stroomberg
- Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Jyotsna Batra
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia
- Translational Research Institute, Brisbane, Queensland, Australia
| | | | - Lisa Horvath
- Chris O’Brien Lifehouse (COBLH), Camperdown, Sydney, NSW, Australia, Sydney, Australia
- Garvan Institute of Medical Research, Sydney, Australia
| | - Judith A. Clements
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia
- Translational Research Institute, Brisbane, Queensland, Australia
| | - Wayne Tilly
- Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, Australia
| | - Gail P. Risbridger
- Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia
- Prostate Cancer Translational Research Program, Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
| | - Henrik Gronberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Markus Aly
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
- Department of Molecular Medicine and Surgery, Karolinska Institutet, and Department of Urology, Karolinska University Hospital, Solna, Stockholm, Sweden
- Department of Urology, Karolinska University Hospital, Stockholm, Sweden
| | - Robert Szulkin
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
- SDS Life Sciences, Stockholm, Sweden
| | - Martin Eklund
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Tobias Nordstrom
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
- Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
| | - Nora Pashayan
- University College London, Department of Applied Health Research, London, UK
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Cambridge, UK
- Department of Applied Health Research, University College London, London, UK
| | - Alison M. Dunning
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Cambridge, UK
| | - Maya Ghoussaini
- Open Targets, Wellcome Sanger Institute, Hinxton, Saffron Walden, Hinxton, UK
| | - Ruth C. Travis
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Tim J. Key
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Elio Riboli
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
| | - Jong Y. Park
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
| | - Thomas A. Sellers
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
| | - Hui-Yi Lin
- School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA
| | - Demetrius Albanes
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Stephanie Weinstein
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Michael B. Cook
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH,, Bethesda, MD, USA
| | - Lorelei A. Mucci
- Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Edward Giovannucci
- Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Sara Lindstrom
- Department of Epidemiology, University of Washington, Seattle, WA, USA
| | - Peter Kraft
- Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - David J. Hunter
- Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Kathryn L. Penney
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA
| | - Constance Turman
- Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA
| | - Catherine M. Tangen
- SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Phyllis J. Goodman
- SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Ian M. Thompson
- CHRISTUS Santa Rosa Hospital – Medical Center, San Antonio, TX, USA
| | - Robert J. Hamilton
- Dept. of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
- Dept. of Surgery (Urology), University of Toronto, Toronto, Canada
| | - Neil E. Fleshner
- Dept. of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
| | - Antonio Finelli
- Division of Urology, Princess Margaret Cancer Centre, Toronto, Canada
| | - Marie-Élise Parent
- Epidemiology and Biostatistics Unit, Centre Armand-Frappier Santé Biotechnologie, Laval, QC, Canada
| | - Janet L. Stanford
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Elaine A. Ostrander
- National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Stella Koutros
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Laura E. Beane Freeman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Meir Stampfer
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA
| | - Alicja Wolk
- Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
| | - Niclas Håkansson
- Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Gerald L. Andriole
- Brady Urological Institute in National Capital Region, Johns Hopkins University, Baltimore, MD, USA
| | - Robert N. Hoover
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Mitchell J. Machiela
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Karina Dalsgaard Sørensen
- Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| | - Michael Borre
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- Department of Urology, Aarhus University Hospital, Aarhus, Denmark
| | - William J. Blot
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- International Epidemiology Institute, Rockville, MD, USA
| | - Wei Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | | | - James E. Mensah
- University of Ghana Medical School, Accra, Ghana
- Korle Bu Teaching Hospital, Accra, Ghana
| | - Yong-Jie Lu
- Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK
| | | | - Ninghan Feng
- Wuxi Second Hospital, Nanjing Medical University, Wuxi, Jiangzhu Province, China
| | - Xueying Mao
- Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK
| | - Yudong Wu
- Department of Urology, First Affiliated Hospital, The Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China
| | - Shan-Chao Zhao
- Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Zan Sun
- The People’s Hospital of Liaoning Proviouce, The People’s Hospital of China Medical University, Shenyang, China, Shenyang, China
| | - Stephen N. Thibodeau
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | | | - Daniel J. Schaid
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA
| | - Catharine M.L. West
- Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Radiotherapy Related Research, The Christie Hospital NHS Foundation Trust, Manchester, UK
| | - Gill Barnett
- University of Cambridge Department of Oncology, Oncology Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
| | | | | | | | - Adam S. Kibel
- Division of Urologic Surgery, Brigham and Womens Hospital, Boston, MA, USA
| | | | - Olivier Cussenot
- GRC 5 Predictive Onco-Urology, Sorbonne Université, Paris, France
- CeRePP, Paris, France
| | | | - Florence Menegaux
- Exposome and Heredity, CESP (UMR 1018), Paris-Saclay Medical School, Paris-Saclay University, Inserm, Gustave Roussy, Villejuif, France
| | - Thérèse Truong
- Exposome and Heredity, CESP (UMR 1018), Paris-Saclay Medical School, Paris-Saclay University, Inserm, Gustave Roussy, Villejuif, France
| | - Yves Akoli Koudou
- Cancer & Environment Group, Center for Research in Epidemiology and Population Health (CESP), INSERM, University Paris-Sud, University Paris-Saclay, Villejuif Cédex, France
| | - Esther M. John
- Department of Medicine, Stanford Cancer Institute,Stanford University School of Medicine, Stanford, CA, USA
| | | | - Lovise Maehle
- Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
| | - Kay-Tee Khaw
- Clinical Gerontology Unit, University of Cambridge, Cambridge, UK
| | - Sue A. Ingles
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
| | - Mariana C Stern
- Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
| | - Ana Vega
- Fundación Pública Galega Medicina Xenómica, Santiago De Compostela, Spain
- Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, Spain
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Spain
| | - Antonio Gómez-Caamaño
- Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain
| | - Laura Fachal
- Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, Spain
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Spain
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
- Fundación Pública Galega Medicina Xenómica, Santiago de Compostela, Spain
| | - Barry S. Rosenstein
- Department of Radiation Oncology and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Sarah L. Kerns
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
| | - Harry Ostrer
- Professor of Pathology and Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA
| | - Manuel R. Teixeira
- Department of Laboratory Genetics, Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center, Porto, Portugal
- Cancer Genetics Group, IPO Porto Research Center (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center, Porto, Portugal
- School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal
| | - Paula Paulo
- Cancer Genetics Group, IPO Porto Research Center (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center, Porto, Portugal
| | - Andreia Brandão
- Cancer Genetics Group, IPO Porto Research Center (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center, Porto, Portugal
| | | | | | - Jeannette T. Bensen
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Ebonee N. Butler
- Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - James L. Mohler
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
| | - Jack A. Taylor
- Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
- Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
| | - Manolis Kogevinas
- ISGlobal, Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Trinidad Dierssen-Sotos
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- University of Cantabria-IDIVAL, Santander, Spain
| | - Gemma Castaño-Vinyals
- ISGlobal, Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- Universitat Pompeu Fabra (UPF), Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | - Lisa Cannon-Albright
- Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, USA
| | - Craig C. Teerlink
- Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, USA
| | - Chad D. Huff
- Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - Patrick Pilie
- Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - Yao Yu
- Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - Ryan J. Bohlender
- Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - Jian Gu
- Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
| | - Sara S. Strom
- The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
| | - Luc Multigner
- Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Rennes, France
| | - Pascal Blanchet
- CHU de Pointe-à-Pitre, Univ Antilles, Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Pointe-à-Pitre, France
| | - Laurent Brureau
- CHU de Pointe-à-Pitre, Univ Antilles, Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Pointe-à-Pitre, France
| | - Radka Kaneva
- Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, Bulgaria
| | - Chavdar Slavov
- Department of Urology and Alexandrovska University Hospital, Medical University of Sofia, Sofia, Bulgaria
| | - Vanio Mitev
- Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, Bulgaria
| | - Robin J. Leach
- Department of Cell Systems and Anatomy and Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
| | - Hermann Brenner
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
- Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany
| | - Xuechen Chen
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | - Ben Schöttker
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Eric A. Klein
- Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA
- Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH, USA
| | - Ann W. Hsing
- Department of Medicine and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
| | | | - Adam B. Murphy
- Department of Urology, Northwestern University, Chicago, IL, USA
| | - Christopher J. Logothetis
- The University of Texas M. D. Anderson Cancer Center, Department of Genitourinary Medical Oncology, Houston, TX, USA
| | - Jeri Kim
- The University of Texas M. D. Anderson Cancer Center, Department of Genitourinary Medical Oncology, Houston, TX, USA
| | - Susan L. Neuhausen
- Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA, USA
| | - Linda Steele
- Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA, USA
| | - Yuan Chun Ding
- Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA, USA
| | - William B. Isaacs
- James Buchanan Brady Urological Institute, Johns Hopkins Hospital and Medical Institution, Baltimore, MD, USA
| | - Barbara Nemesure
- Department of Family, Population and Preventive Medicine, Stony Brook University, Stony Brook, NY, USA
| | - Anselm J.M. Hennis
- Department of Family, Population and Preventive Medicine, Stony Brook University, Stony Brook, NY, USA
- Chronic Disease Research Centre and Faculty of Medical Sciences, University of the West Indies, Bridgetown, Barbados
| | - John Carpten
- Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | | | | | - Kim De Ruyck
- Ghent University, Faculty of Medicine and Health Sciences, Basic Medical Sciences, Ghent, Belgium
| | - Gert De Meerleer
- Ghent University Hospital, Department of Radiotherapy, Ghent, Belgium
| | - Piet Ost
- Ghent University Hospital, Department of Radiotherapy, Ghent, Belgium
| | - Jianfeng Xu
- Program for Personalized Cancer Care and Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA
| | - Azad Razack
- Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Jasmine Lim
- Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Soo-Hwang Teo
- Cancer Research Malaysia (CRM), Outpatient Centre, Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia
| | - Lisa F. Newcomb
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Department of Urology, University of Washington, Seattle, WA, USA
| | - Daniel W. Lin
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Department of Urology, University of Washington, Seattle, WA, USA
| | - Jay H. Fowke
- Department of Preventive Medicine, Division of Epidemiology,The University of Tennessee Health Science Center, Memphis, TN, USA
| | | | - Benjamin A. Rybicki
- Department of Public Health Sciences, Henry Ford Hospital, Detroit, Detroit, MI, USA
| | - Marija Gamulin
- Division of Medical Oncology, Urogenital Unit, Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Davor Lessel
- Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Tomislav Kulis
- Department of Urology, University Hospital Center Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia
| | - Nawaid Usmani
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
- Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada
| | - Aswin Abraham
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
- Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada
| | - Sandeep Singhal
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - Matthew Parliament
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
- Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada
| | - Frank Claessens
- Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, Leuven, Belgium
| | - Steven Joniau
- Department of Urology, University Hospitals Leuven, Leuven, Belgium
| | - Thomas Van den Broeck
- Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, Leuven, Belgium
- Department of Urology, University Hospitals Leuven, Leuven, Belgium
| | - Manuela Gago-Dominguez
- Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saúde, SERGAS, Santiago de Compostela, Spain
- University of California San Diego, Moores Cancer Center, La Jolla, CA, USA
| | - Jose Esteban Castelao
- Genetic Oncology Unit, CHUVI Hospital, Complexo Hospitalario Universitario de Vigo, Instituto de Investigación Biomédica Galicia Sur (IISGS), Vigo (Pontevedra), Spain
| | - Maria Elena Martinez
- University of California San Diego, Moores Cancer Center, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA
| | - Samantha Larkin
- Scientific Education Support, Thames Ditton, Surrey, Formerly Cancer Sciences, University of Southampton, Southampton, UK
| | - Paul A. Townsend
- School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Surrey, UK
| | | | - William S. Bush
- Department of Population and Quantitative Health Sciences, Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA
| | - Melinda C. Aldrich
- Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Dana C. Crawford
- Department of Population and Quantitative Health Sciences, Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA
| | - Shiv Srivastava
- Department of Biochemistry and Molecular & Cellular Biology, Georgetown University Medical Center, Washington, DC, USA
| | - Jennifer Cullen
- Department of Population and Quantitative Health Sciences, Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, OH, USA
- Department of Surgery, Center for Prostate Disease Research,Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Gyorgy Petrovics
- Department of Surgery, Center for Prostate Disease Research,Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Graham Casey
- Department of Public Health Science, Center for Public Health Genomics,University of Virginia, Charlottesville, VA, USA
| | - Ying Wang
- Department of Population Science, American Cancer Society, Kennesaw, GA, USA
| | - Yao Tettey
- Korle Bu Teaching Hospital, Accra, Ghana
- Department of Pathology, University of Ghana, Accra, Ghana
| | - Joseph Lachance
- School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA
| | - Wei Tang
- Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | | | - Andrew A. Adjei
- Department of Pathology, University of Ghana Medical School, Accra, Ghana
| | - Evelyn Tay
- Korle Bu Teaching Hospital, Accra, Ghana
| | | | | | - Kosj Yamoah
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA
| | | | | | - Jacob M. Keaton
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- Center for Precision Health Research, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Jacklyn N. Hellwege
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- Division of Genetic Medicine, Department of Medicine, Vanderbilt Genetics Institute, Nashville, TN, USA
| | - Peter E. Clark
- Atrium Health/Levine Cancer Institute, Charlotte, NC, USA
| | | | | | | | - Olufemi Ogunbiyi
- Department of Pathology, College of Medicine, University of Ibadan, Ibadan, Nigeria
| | - Olayiwola Shittu
- Department of Surgery, College of Medicine, University of Ibadan and Univerity College Hospital, Ibadan, Nigeria
| | - Olukemi Amodu
- Institute of Child Health, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria
| | - Akindele O. Adebiyi
- Clinical Epidemiology Unit, Department of Community Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria
| | - Oseremen I. Aisuodionoe-Shadrach
- College of Health Sciences, University of Abuja, University of Abuja Teaching Hospital and Cancer Science Center, Abuja, Nigeria
| | - Hafees O. Ajibola
- College of Health Sciences, University of Abuja, University of Abuja Teaching Hospital and Cancer Science Center, Abuja, Nigeria
| | - Mustapha A. Jamda
- College of Health Sciences, University of Abuja, University of Abuja Teaching Hospital and Cancer Science Center, Abuja, Nigeria
| | - Olabode P. Oluwole
- College of Health Sciences, University of Abuja, University of Abuja Teaching Hospital and Cancer Science Center, Abuja, Nigeria
| | - Maxwell Nwegbu
- College of Health Sciences, University of Abuja, University of Abuja Teaching Hospital and Cancer Science Center, Abuja, Nigeria
| | | | | | | | - Halimatou Diop
- Laboratoires Bacteriologie et Virologie, Hôpital Aristide Le Dantec, Dakar, Senegal
| | - Susan M. Gundell
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Monique J. Roobol
- Department of Urology, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Guido Jenster
- Department of Urology, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Ron H.N. van Schaik
- Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, Netherlands
| | - Jennifer J. Hu
- The University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA
| | - Maureen Sanderson
- Department of Family and Community Medicine, Meharry Medical College, Nashville, TN, USA
| | - Linda Kachuri
- Department of Epidemiology and Population Health, Stanford Cancer Institute, Stanford, CA, USA
| | - Rohit Varma
- Southern California Eye Institute, CHA Hollywood Presbyterian Medical Center, Los Angeles, CA, USA
| | - Roberta McKean-Cowdin
- Department of Population and Public Health Sciences, Keck School of Medicine,University of Southern California, Los Angeles, CA, USA
| | - Mina Torres
- Southern California Eye Institute, CHA Hollywood Presbyterian Medical Center, Los Angeles, CA, USA
| | - Michael H. Preuss
- The Charles Bronfman Institute for Personalized Medicine,Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ruth J.F. Loos
- The Charles Bronfman Institute for Personalized Medicine,Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Matthew Zawistowski
- Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA
- Center for Statistical Genetics, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | - Sebastian Zöllner
- Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA
- Center for Statistical Genetics, University of Michigan School of Public Health, Ann Arbor, MI, USA
- Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA
| | - Zeyun Lu
- Department of Population and Public Health Sciences, Keck School of Medicine,University of Southern California, Los Angeles, CA, USA
| | | | - Douglas F. Easton
- Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology,, Cambridge, UK
| | - Stefan Ambs
- Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
| | - Todd L. Edwards
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Reedik Mägi
- Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia
| | - Timothy R. Rebbeck
- Harvard TH Chan School of Public Health and Division of Population Sciences, Dana Farber Cancer Institute, Boston, MA, USA
| | - Lars Fritsche
- Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA
| | - Stephen J. Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Sonja I. Berndt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA
| | - Fredrik Wiklund
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Hidewaki Nakagawa
- Laboratory for Cancer Genomics, RIKEN Center of Integrative Medical Sciences, Yokohama, Japan
| | - John S. Witte
- Department of Epidemiology and Population Health, Stanford Cancer Institute, Stanford, CA, USA
- Departments of Biomedical Data Science, Stanford University, Stanford, CA, USA
| | - J. Michael Gaziano
- Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
- VA Boston Healthcare System, Boston, MA, USA
| | | | - Nick Mancuso
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Chikashi Terao
- Laboratory for Statistical and Translational Genetics, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
- Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan
- The Department of Applied Genetics, School of Pharmaceutical Sciences, Shizuoka, Japan
| | - Rosalind A. Eeles
- The Institute of Cancer Research, London, UK
- Royal Marsden NHS Foundation Trust, London, UK
| | | | | | - David V. Conti
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Christopher A. Haiman
- Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| |
Collapse
|
2
|
Pakarainen T, Nevalainen J, Talala K, Taari K, Raitanen J, Kujala P, Stenman UH, Tammela TL, Auvinen A. The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC). Clin Cancer Res 2018; 25:839-843. [DOI: 10.1158/1078-0432.ccr-18-1807] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2018] [Revised: 09/07/2018] [Accepted: 10/09/2018] [Indexed: 11/16/2022]
|
3
|
Ahlgren GM, Flodgren P, Tammela TL, Kellokumpu-Lehtinen P, Borre M, Angelsen A, Iversen JR, Sverrisdottir A, Jonsson E, Sengelov L. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. Eur Urol 2018; 73:870-876. [DOI: 10.1016/j.eururo.2018.01.012] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2017] [Accepted: 01/11/2018] [Indexed: 11/17/2022]
|
4
|
Murtola TJ, Virkku A, Talala K, Stenman UH, Taari K, Tammela TL, Auvinen A. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use. J Urol 2017; 198:305-309. [DOI: 10.1016/j.juro.2017.02.069] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/09/2017] [Indexed: 11/29/2022]
Affiliation(s)
- Teemu J. Murtola
- Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
- Department of Urology, Tampere University Hospital, Tampere, Finland
| | - Anniina Virkku
- Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
| | | | - Ulf-Håkan Stenman
- Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - Kimmo Taari
- Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - Teuvo L.J. Tammela
- Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland
- Department of Urology, Tampere University Hospital, Tampere, Finland
| | - Anssi Auvinen
- Faculty of Social Sciences, University of Tampere, Tampere, Finland
| |
Collapse
|
5
|
Affiliation(s)
| | - Andres Kotsar
- Department of Urology, Tarto University Hospital, Tarto, Estonia
| | - Teuvo L.J. Tammela
- School of Medicine, University of Tampere, Tampere, Finland
- Department of Urology, Tampere University Hospital, Tampere, Finland
| | - Teemu J. Murtola
- School of Medicine, University of Tampere, Tampere, Finland
- Department of Urology, Tampere University Hospital, Tampere, Finland
| |
Collapse
|
6
|
Luedeke M, Rinckleb AE, FitzGerald LM, Geybels MS, Schleutker J, Eeles RA, Teixeira MR, Cannon-Albright L, Ostrander EA, Weikert S, Herkommer K, Wahlfors T, Visakorpi T, Leinonen KA, Tammela TL, Cooper CS, Kote-Jarai Z, Edwards S, Goh CL, McCarthy F, Parker C, Flohr P, Paulo P, Jerónimo C, Henrique R, Krause H, Wach S, Lieb V, Rau TT, Vogel W, Kuefer R, Hofer MD, Perner S, Rubin MA, Agarwal AM, Easton DF, Al Olama AA, Benlloch S, Hoegel J, Stanford JL, Maier C. Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. Hum Mol Genet 2016; 25:5490-5499. [PMID: 27798103 PMCID: PMC5418832 DOI: 10.1093/hmg/ddw349] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Revised: 09/23/2016] [Accepted: 10/07/2016] [Indexed: 12/15/2022] Open
Abstract
Molecular and epidemiological differences have been described between TMPRSS2:ERG fusion-positive and fusion-negative prostate cancer (PrCa). Assuming two molecularly distinct subtypes, we have examined 27 common PrCa risk variants, previously identified in genome-wide association studies, for subtype specific associations in a total of 1221 TMPRSS2:ERG phenotyped PrCa cases. In meta-analyses of a discovery set of 552 cases with TMPRSS2:ERG data and 7650 unaffected men from five centers we have found support for the hypothesis that several common risk variants are associated with one particular subtype rather than with PrCa in general. Risk variants were analyzed in case-case comparisons (296 TMPRSS2:ERG fusion-positive versus 256 fusion-negative cases) and an independent set of 669 cases with TMPRSS2:ERG data was established to replicate the top five candidates. Significant differences (P < 0.00185) between the two subtypes were observed for rs16901979 (8q24) and rs1859962 (17q24), which were enriched in TMPRSS2:ERG fusion-negative (OR = 0.53, P = 0.0007) and TMPRSS2:ERG fusion-positive PrCa (OR = 1.30, P = 0.0016), respectively. Expression quantitative trait locus analysis was performed to investigate mechanistic links between risk variants, fusion status and target gene mRNA levels. For rs1859962 at 17q24, genotype dependent expression was observed for the candidate target gene SOX9 in TMPRSS2:ERG fusion-positive PrCa, which was not evident in TMPRSS2:ERG negative tumors. The present study established evidence for the first two common PrCa risk variants differentially associated with TMPRSS2:ERG fusion status. TMPRSS2:ERG phenotyping of larger studies is required to determine comprehensive sets of variants with subtype-specific roles in PrCa.
Collapse
Affiliation(s)
- Manuel Luedeke
- Institute of Human Genetics, University of Ulm, Ulm, Germany
- Department of Urology, University of Ulm, Ulm, Germany
| | - Antje E. Rinckleb
- Institute of Human Genetics, University of Ulm, Ulm, Germany
- Department of Urology, University of Ulm, Ulm, Germany
| | - Liesel M. FitzGerald
- Fred Hutchinson Cancer Research Center, Division of Public Health Science, Seattle, Washington, USA
- Cancer, Genetics and Immunology, Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia
| | - Milan S. Geybels
- Fred Hutchinson Cancer Research Center, Division of Public Health Science, Seattle, Washington, USA
| | - Johanna Schleutker
- Institute of Biomedical Technology/BioMediTech, University of Tampere, Tampere, Finland
- Department of Medical Biochemistry and Genetics, University of Turku, and Tyks Microbiology and Genetics, Department of Medical Genetics, Turku University Hospital, Turku, Finland
| | - Rosalind A. Eeles
- The Institute of Cancer Research, London, UK
- Royal Marsden National Health Service Foundation Trust, London and Sutton, UK
| | - Manuel R. Teixeira
- Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
- Abel Salazar Biomedical Sciences Institute, Porto University, Porto, Portugal
| | - Lisa Cannon-Albright
- Division of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, USA
| | | | - Steffen Weikert
- Department of Urology, Vivantes Humboldt Hospital, Berlin, Germany
- Department of Urology, University Hospital Charité, Berlin, Germany
| | - Kathleen Herkommer
- Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - Tiina Wahlfors
- Institute of Biomedical Technology/BioMediTech, University of Tampere, Tampere, Finland
| | - Tapio Visakorpi
- Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | | | - Teuvo L.J. Tammela
- Department of Urology, Tampere University Hospital and School of Medicine, University of Tampere, Tampere, Finland
| | - Colin S. Cooper
- The Institute of Cancer Research, London, UK
- Department of Biological Science, University of East Anglia, Norwich, UK
| | | | | | - Chee L. Goh
- The Institute of Cancer Research, London, UK
| | | | - Chris Parker
- Royal Marsden National Health Service Foundation Trust, London and Sutton, UK
| | - Penny Flohr
- The Institute of Cancer Research, London, UK
| | - Paula Paulo
- Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
- Abel Salazar Biomedical Sciences Institute, Porto University, Porto, Portugal
| | - Carmen Jerónimo
- Abel Salazar Biomedical Sciences Institute, Porto University, Porto, Portugal
- Department of Pathology, Portuguese Oncology Institute, Porto, Portugal
| | - Rui Henrique
- Abel Salazar Biomedical Sciences Institute, Porto University, Porto, Portugal
- Department of Pathology, Portuguese Oncology Institute, Porto, Portugal
| | - Hans Krause
- Department of Urology, University Hospital Charité, Berlin, Germany
| | - Sven Wach
- Department of Urology, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany
| | - Verena Lieb
- Department of Urology, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany
| | - Tilman T. Rau
- Institute of Pathology, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany
- Institute of Pathology, University Bern, Bern Switzerland
| | - Walther Vogel
- Institute of Human Genetics, University of Ulm, Ulm, Germany
| | - Rainer Kuefer
- Department of Urology, Klinik am Eichert, Göppingen, Germany
| | - Matthias D. Hofer
- Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Sven Perner
- Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck and the Research Center Borstel, Leibniz Center for Medicine and Biosciences, Luebeck and Borstel, Germany
| | - Mark A. Rubin
- Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY, USA
| | | | - Doug F. Easton
- Centre for Cancer Genetics Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Ali Amin Al Olama
- Centre for Cancer Genetics Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - Sara Benlloch
- Centre for Cancer Genetics Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | | | - Josef Hoegel
- Institute of Human Genetics, University of Ulm, Ulm, Germany
| | - Janet L. Stanford
- Fred Hutchinson Cancer Research Center, Division of Public Health Science, Seattle, Washington, USA
- Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, USA
| | - Christiane Maier
- Institute of Human Genetics, University of Ulm, Ulm, Germany
- Department of Urology, University of Ulm, Ulm, Germany
| |
Collapse
|
7
|
Syvälä H, Pennanen P, Bläuer M, Tammela TL, Murtola TJ. Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells. Biochem Biophys Res Commun 2016; 481:46-50. [DOI: 10.1016/j.bbrc.2016.11.021] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Accepted: 11/05/2016] [Indexed: 01/09/2023]
|
8
|
Nurminen R, Rantapero T, Wong SC, Fischer D, Lehtonen R, Tammela TL, Nykter M, Visakorpi T, Wahlfors T, Schleutker J. Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifiesDGAT2as a new target gene. Genes Chromosomes Cancer 2016; 55:661-73. [DOI: 10.1002/gcc.22368] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2015] [Revised: 04/17/2016] [Accepted: 04/20/2016] [Indexed: 01/17/2023] Open
Affiliation(s)
- Riikka Nurminen
- BioMediTech and Prostate Cancer Research Center; University of Tampere; Tampere Finland
- Fimlab Laboratories; Tampere University Hospital; Tampere Finland
| | - Tommi Rantapero
- BioMediTech and Prostate Cancer Research Center; University of Tampere; Tampere Finland
- Fimlab Laboratories; Tampere University Hospital; Tampere Finland
| | - Swee C. Wong
- Department of Biosciences; University of Helsinki; Helsinki Finland
| | - Daniel Fischer
- BioMediTech and Prostate Cancer Research Center; University of Tampere; Tampere Finland
- Fimlab Laboratories; Tampere University Hospital; Tampere Finland
| | - Rainer Lehtonen
- Institute of Biomedicine & Genome-Scale Biology Research Program, Faculty of Medicine, Biomedicum, University of Helsinki; Helsinki Finland
| | - Teuvo L.J. Tammela
- Department of Urology and Prostate Cancer Research Center; University of Tampere and Tampere University Hospital; Tampere Finland
| | - Matti Nykter
- BioMediTech and Prostate Cancer Research Center; University of Tampere; Tampere Finland
| | - Tapio Visakorpi
- BioMediTech and Prostate Cancer Research Center; University of Tampere; Tampere Finland
- Fimlab Laboratories; Tampere University Hospital; Tampere Finland
| | - Tiina Wahlfors
- BioMediTech and Prostate Cancer Research Center; University of Tampere; Tampere Finland
- Fimlab Laboratories; Tampere University Hospital; Tampere Finland
| | - Johanna Schleutker
- BioMediTech and Prostate Cancer Research Center; University of Tampere; Tampere Finland
- Department of Medical Biochemistry and Genetics; University of Turku; Turku Finland
- Tyks Microbiology and Genetics, Department of Medical Genetics, Turku University Hospital; Turku Finland
| |
Collapse
|
9
|
Ylipää A, Kivinummi K, Annala M, Kohvakka A, Latonen L, Scaravilli M, Kartasalo K, Leppänen SP, Karakurt S, Seppälä J, Yli-Harja O, Tammela TL, Zhang W, Visakorpi T, Nykter M. Abstract 148: Transcriptome sequencing reveals PCAT5 - new ERG-regulated non-coding transcript in prostate cancer. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Prostate cancer (PC) is the second most common cancer among men. Most PC-related deaths are due to invasive tumors that are treated with therapies inhibiting androgen production or androgen receptor (AR) activity. After an initial response, tumors invariably progress to castration resistant prostate cancers (CRPCs) for which no effective cure exists.
Methods and Results: We used transcriptome sequencing to study fresh-frozen tissue specimens from 12 benign prostatic hyperplasias (BPHs), 28 PCs, and 13 CRPCs. Reference-based transcriptome assembly uncovered 145 previously unannotated intergenic PC and CRPC associated long non-coding transcripts (lncRNAs) or isoforms. One third of the transcripts were CRPC-specific. We showed that one of the novel transcripts, Prostate Cancer Associated Transcript 5 (PCAT5), expressed in half of the tumors, was likely regulated by ERG, the key transcription factor in ∼50% of prostate cancers. Genome-wide expression analysis of a PCAT5-positive prostate cancer cell line after PCAT5 knockdown suggested significant alterations in proliferation pathways. In vitro validation of the pathway alterations revealed concordantly dramatic effects in phenotype: stalling of cell growth, migration, invasion, and colony forming potential, and increase in the rate of apoptosis.
Conclusions: We identified the key differences between PC and CRPC in transcriptome level, and validated the oncogenic potential of a novel lncRNA in ERG-positive prostate cancers, PCAT5. Our study presents a number of putative lncRNA biomarkers for CRPC, and opportunities for therapeutic intervention.
Citation Format: Antti Ylipää, Kati Kivinummi, Matti Annala, Annika Kohvakka, Leena Latonen, Mauro Scaravilli, Kimmo Kartasalo, Simo-Pekka Leppänen, Serdar Karakurt, Janne Seppälä, Olli Yli-Harja, Teuvo L.J. Tammela, Wei Zhang, Tapio Visakorpi, Matti Nykter. Transcriptome sequencing reveals PCAT5 - new ERG-regulated non-coding transcript in prostate cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 148. doi:10.1158/1538-7445.AM2015-148
Collapse
Affiliation(s)
- Antti Ylipää
- 1Department of Signal Processing, Tampere University of Technology, Tampere, Finland
| | - Kati Kivinummi
- 1Department of Signal Processing, Tampere University of Technology, Tampere, Finland
| | - Matti Annala
- 1Department of Signal Processing, Tampere University of Technology, Tampere, Finland
| | | | - Leena Latonen
- 2BioMediTech, University of Tampere, Tampere, Finland
| | | | - Kimmo Kartasalo
- 1Department of Signal Processing, Tampere University of Technology, Tampere, Finland
| | - Simo-Pekka Leppänen
- 1Department of Signal Processing, Tampere University of Technology, Tampere, Finland
| | | | - Janne Seppälä
- 1Department of Signal Processing, Tampere University of Technology, Tampere, Finland
| | - Olli Yli-Harja
- 1Department of Signal Processing, Tampere University of Technology, Tampere, Finland
| | - Teuvo L.J. Tammela
- 3Department of Urology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland
| | - Wei Zhang
- 4Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX
| | | | - Matti Nykter
- 1Department of Signal Processing, Tampere University of Technology, Tampere, Finland
| |
Collapse
|
10
|
Laitinen VH, Rantapero T, Fischer D, Vuorinen EM, Tammela TL, Wahlfors T, Schleutker J. Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer. Int J Cancer 2015; 136:2316-27. [PMID: 25335771 PMCID: PMC4355047 DOI: 10.1002/ijc.29276] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2014] [Accepted: 10/01/2014] [Indexed: 01/13/2023]
Abstract
The 2q37 and 17q12-q22 loci are linked to an increased prostate cancer (PrCa) risk. No candidate gene has been localized at 2q37 and the HOXB13 variant G84E only partially explains the linkage to 17q21-q22 observed in Finland. We screened these regions by targeted DNA sequencing to search for cancer-associated variants. Altogether, four novel susceptibility alleles were identified. Two ZNF652 (17q21.3) variants, rs116890317 and rs79670217, increased the risk of both sporadic and hereditary PrCa (rs116890317: OR = 3.3-7.8, p = 0.003-3.3 × 10(-5) ; rs79670217: OR = 1.6-1.9, p = 0.002-0.009). The HDAC4 (2q37.2) variant rs73000144 (OR = 14.6, p = 0.018) and the EFCAB13 (17q21.3) variant rs118004742 (OR = 1.8, p = 0.048) were overrepresented in patients with familial PrCa. To map the variants within 2q37 and 17q11.2-q22 that may regulate PrCa-associated genes, we combined DNA sequencing results with transcriptome data obtained by RNA sequencing. This expression quantitative trait locus (eQTL) analysis identified 272 single-nucleotide polymorphisms (SNPs) possibly regulating six genes that were differentially expressed between cases and controls. In a modified approach, prefiltered PrCa-associated SNPs were exploited and interestingly, a novel eQTL targeting ZNF652 was identified. The novel variants identified in this study could be utilized for PrCa risk assessment, and they further validate the suggested role of ZNF652 as a PrCa candidate gene. The regulatory regions discovered by eQTL mapping increase our understanding of the relationship between regulation of gene expression and susceptibility to PrCa and provide a valuable starting point for future functional research.
Collapse
Affiliation(s)
- Virpi H. Laitinen
- BioMediTech, University of Tampere and Fimlab Laboratories, FI-33520 Tampere, Finland
| | - Tommi Rantapero
- BioMediTech, University of Tampere and Fimlab Laboratories, FI-33520 Tampere, Finland
| | - Daniel Fischer
- School of Health Sciences, University of Tampere, FI-33014 Tampere, Finland
| | - Elisa M. Vuorinen
- BioMediTech, University of Tampere and Fimlab Laboratories, FI-33520 Tampere, Finland
| | - Teuvo L.J. Tammela
- Department of Urology, Tampere University Hospital and Medical School, University of Tampere, FI-33520 Tampere, Finland
| | | | - Tiina Wahlfors
- BioMediTech, University of Tampere and Fimlab Laboratories, FI-33520 Tampere, Finland
| | - Johanna Schleutker
- BioMediTech, University of Tampere and Fimlab Laboratories, FI-33520 Tampere, Finland
- Medical Biochemistry and Genetics, Institute of Biomedicine, FI-20014 University of Turku, Turku, Finland
| |
Collapse
|
11
|
Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Canzian F, Riboli E, Key TJ, Andriole G, Albanes D, Hayes RB, Schleutker J, Auvinen A, Tammela TL, Weischer M, Stanford JL, Ostrander EA, Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dörk T, Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English D, Virtamo J, Le Marchand L, Campa D, Kaaks R, Lindstrom S, Diver WR, Gapstur S, Yeager M, Cox A, Stern MC, Corral R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng SL, Wahlfors T, Taari K, Kujala P, Klarskov P, Nordestgaard BG, Røder MA, Frikke-Schmidt R, Bojesen SE, FitzGerald LM, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Rinckleb A, Luedeke M, Herkommer K, Meyer A, Serth J, Marthick JR, Patterson B, Wokolorczyk D, Spurdle A, Lose F, McDonnell SK, Joshi AD, Shahabi A, Pinto P, Santos J, Ray A, Sellers TA, Lin HY, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V, Chanock S, Gronberg H, Haiman CA, Kraft P, Easton DF, Eeles RA. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet 2013; 22:408-15. [PMID: 23065704 PMCID: PMC3526158 DOI: 10.1093/hmg/dds425] [Citation(s) in RCA: 109] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2012] [Accepted: 10/04/2012] [Indexed: 01/14/2023] Open
Abstract
Genome-wide association studies (GWAS) have identified multiple common genetic variants associated with an increased risk of prostate cancer (PrCa), but these explain less than one-third of the heritability. To identify further susceptibility alleles, we conducted a meta-analysis of four GWAS including 5953 cases of aggressive PrCa and 11 463 controls (men without PrCa). We computed association tests for approximately 2.6 million SNPs and followed up the most significant SNPs by genotyping 49 121 samples in 29 studies through the international PRACTICAL and BPC3 consortia. We not only confirmed the association of a PrCa susceptibility locus, rs11672691 on chromosome 19, but also showed an association with aggressive PrCa [odds ratio = 1.12 (95% confidence interval 1.03-1.21), P = 1.4 × 10(-8)]. This report describes a genetic variant which is associated with aggressive PrCa, which is a type of PrCa associated with a poorer prognosis.
Collapse
Affiliation(s)
- Ali Amin Al Olama
- Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Worts Causeway, Cambridge CB1 8RN, UK
| | - Zsofia Kote-Jarai
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Fredrick R. Schumacher
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Fredrik Wiklund
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm SE-171 77, Sweden
| | - Sonja I. Berndt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
- Core Genotyping Facility, SAIC-Frederick, Inc., National Cancer Institute, NIH, Gaithersburg, MD, USA
| | - Sara Benlloch
- Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Worts Causeway, Cambridge CB1 8RN, UK
| | - Graham G. Giles
- Cancer Epidemiology Centre, Cancer Council Victoria, 1 Rathdowne Street, Carlton, VIC 3053, Australia
- Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, 723 Swanston Street, Carlton, VIC 3053, Australia
| | - Gianluca Severi
- Cancer Epidemiology Centre, Cancer Council Victoria, 1 Rathdowne Street, Carlton, VIC 3053, Australia
- Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, 723 Swanston Street, Carlton, VIC 3053, Australia
| | - David E. Neal
- Surgical Oncology (Uro-Oncology: S4), Addenbrooke's Hospital, University of Cambridge, Box 279, Hills Road, Cambridge, UK
- Li Ka Shing Centre, Cancer Research UK Cambridge Research Institute, Cambridge CB2 2QQ, UK
| | - Freddie C. Hamdy
- Nuffield Department of Surgery and
- Faculty of Medical Science, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK
| | - Jenny L. Donovan
- School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK
| | - David J. Hunter
- Program in Molecular and Genetic Epidemiology, Department of Epidemiology and
| | - Brian E. Henderson
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Michael J. Thun
- Epidemiology Research Program, American Cancer Society, Atlanta, GA 30303, USA
| | - Michael Gaziano
- Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC) and Geriatric Research, Education, and Clinical Center (GRECC), Boston Veterans Affairs Healthcare System, Boston, MA 02114, USA
- Division of Aging, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215, USA
| | | | - Afshan Siddiq
- Department of Genomics of Common Disease, School of Public Health, Imperial College, London SW7 2AZ, UK
| | - Ruth C. Travis
- Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
| | - David G. Cox
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK
- Lyon Cancer Research Center, INSERM U1052, Lyon, France
| | | | - Elio Riboli
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, UK
| | - Timothy J. Key
- Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
| | - Gerald Andriole
- Division of Urologic Surgery, Washington University School of Medicine, St Louis, MO, USA
| | - Demetrius Albanes
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
| | - Richard B. Hayes
- Division of Epidemiology, Department of Environmental Medicine, NYU Langone Medical Centre, NYU Cancer Institute, New York, NY 10016, USA
| | - Johanna Schleutker
- Institute of Biomedical Technology/BioMediTech, University of Tampere and
- Department of Medical Biochemistry and Genetics, University of Turku, Turku, Finland
| | - Anssi Auvinen
- Department of Epidemiology, School of Health Sciences and
| | - Teuvo L.J. Tammela
- Department of Urology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland
| | | | - Janet L. Stanford
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA
- Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA
| | - Elaine A. Ostrander
- National Human Genome Research Institute, National Institutes of Health, 50 South Drive, Room 5351, Bethesda, MD, USA
| | - Cezary Cybulski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Jan Lubinski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | | | | | | | - Jyotsna Batra
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia
| | - Judith A. Clements
- Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia
| | - Suzanne Chambers
- Griffith Health Institute, Griffith University, Gold Coast, QLD, Australia
- Viertel Centre for Research in Cancer Control, Cancer Council Queensland, Brisbane, QLD, Australia
- Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia
| | - Joanne Aitken
- Viertel Centre for Research in Cancer Control, Cancer Council Queensland, Brisbane, QLD, Australia
| | - Robert A. Gardiner
- Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia
| | - Christiane Maier
- Department of Urology and
- Institute of Human Genetics, University Hospital Ulm, Ulm, Germany
| | - Walther Vogel
- Institute of Human Genetics, University Hospital Ulm, Ulm, Germany
| | - Thilo Dörk
- Hannover Medical School, Hannover, Germany
| | | | - Tomonori Habuchi
- Department of Urology,Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Sue Ingles
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Esther M. John
- Cancer Prevention Institute of California, Fremont, CA, USA
- Division of Epidemiology, Department of Health Research and Policy and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
| | - Joanne L. Dickinson
- Menzies Research Institute Tasmania, University of Tasmania, Hobart, TAS, Australia
| | - Lisa Cannon-Albright
- Division of Genetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
- George E. Wahlen Department of Veterans Affairs Medical Centre, Salt Lake City, UT, USA
| | - Manuel R. Teixeira
- Department of Genetics, Portuguese Oncology Institute and Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal
| | - Radka Kaneva
- Molecular Medicine Centre, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, 2 Zdrave St, Sofia 1431, Bulgaria
| | - Hong-Wei Zhang
- Department of Epidemiology, Second Military Medical University, Shanghai, China
| | - Yong-Jie Lu
- Centre for Molecular Oncology and Imaging, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, UK
| | - Jong Y. Park
- Division of Cancer Prevention and Control, H. Lee Moffitt Cancer Centre, 12902 Magnolia Drive, Tampa, FL, USA
| | - Kathleen A. Cooney
- Department of Internal Medicine and
- Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA
| | | | | | - Edward Saunders
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | | | - Nadiya Mahmud
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Michelle Guy
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Koveela Govindasami
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Lynne T. O'Brien
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | | | - Amanda L. Hall
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Emma J. Sawyer
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Tokhir Dadaev
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | - Jonathan Morrison
- Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Worts Causeway, Cambridge CB1 8RN, UK
| | - David P. Dearnaley
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Alan Horwich
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Robert A. Huddart
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Vincent S. Khoo
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Christopher C. Parker
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Nicholas Van As
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | | | - Alan Thompson
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Tim Dudderidge
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Chris Ogden
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| | - Colin S. Cooper
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
| | | | - Melissa C. Southey
- Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Grattan street, Parkville, VIC, Australia
| | - John L. Hopper
- Cancer Epidemiology Centre, Cancer Council Victoria, 1 Rathdowne Street, Carlton, VIC, Australia
| | - Dallas English
- Cancer Epidemiology Centre, Cancer Council Victoria, 1 Rathdowne Street, Carlton, VIC, Australia
- Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, 723 Swanston Street, Carlton, VIC, Australia
| | - Jarmo Virtamo
- Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
| | - Loic Le Marchand
- Epidemiology Program, University of Hawaii Cancer Centre, Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
| | - Daniele Campa
- Lyon Cancer Research Center, INSERM U1052, Lyon, France
| | - Rudolf Kaaks
- Division of Cancer Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany
| | - Sara Lindstrom
- Program in Molecular and Genetic Epidemiology, Department of Epidemiology and
| | - W. Ryan Diver
- Epidemiology Research Program, American Cancer Society, Atlanta, GA 30303, USA
| | - Susan Gapstur
- Epidemiology Research Program, American Cancer Society, Atlanta, GA 30303, USA
| | - Meredith Yeager
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
- Core Genotyping Facility, SAIC-Frederick, Inc., National Cancer Institute, NIH, Gaithersburg, MD, USA
| | - Angela Cox
- Department of Oncology, University of Sheffield, Sheffield, UK
| | - Mariana C. Stern
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Roman Corral
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Markus Aly
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm SE-171 77, Sweden
- Division of Urology, Department of Clinical Sciences, Danderyd Hospital and
| | - William Isaacs
- School of Medicine, Johns Hopkins University, 115 Marburg Building, 600 North Wolfe Street, Baltimore, MD 21205, USA
| | - Jan Adolfsson
- Oncological Centre, CLINTEC, Karolinska Institute, Stockholm, Sweden
| | - Jianfeng Xu
- Center for Cancer Genomics, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
| | - S. Lilly Zheng
- Center for Cancer Genomics, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
| | - Tiina Wahlfors
- Department of Urology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland
| | - Kimmo Taari
- Department of Urology, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland
| | - Paula Kujala
- Department of Pathology, Centre for Laboratory Medicine, Tampere University Hospital, Tampere, Finland
| | - Peter Klarskov
- Department of Urology, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, Herlev DK-2730, Denmark
| | | | | | - Ruth Frikke-Schmidt
- Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen DK-2100, Denmark
| | | | - Liesel M. FitzGerald
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA
| | - Suzanne Kolb
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA
| | - Erika M. Kwon
- National Human Genome Research Institute, National Institutes of Health, 50 South Drive, Room 5351, Bethesda, MD, USA
| | - Danielle M. Karyadi
- National Human Genome Research Institute, National Institutes of Health, 50 South Drive, Room 5351, Bethesda, MD, USA
| | | | - Michael Borre
- Department of Urology, Aarhus University Hospital, Skejby, Denmark
| | | | - Manuel Luedeke
- Institute of Human Genetics, University Hospital Ulm, Ulm, Germany
| | - Kathleen Herkommer
- Department of Urology, Rechts der Isar Medical Centre, Technical University of Munich, Munich, Germany
| | | | | | - James R. Marthick
- Menzies Research Institute Tasmania, University of Tasmania, Hobart, TAS, Australia
| | - Briony Patterson
- Menzies Research Institute Tasmania, University of Tasmania, Hobart, TAS, Australia
| | - Dominika Wokolorczyk
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | | | - Felicity Lose
- Molecular Cancer Epidemiology Laboratory, Queensland Institute of Medical Research, Brisbane, QLD, Australia
| | | | - Amit D. Joshi
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Ahva Shahabi
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Pedro Pinto
- Department of Genetics, Portuguese Oncology Institute and Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal
| | - Joana Santos
- Department of Genetics, Portuguese Oncology Institute and Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal
| | - Ana Ray
- Department of Internal Medicine and
- Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA
| | - Thomas A. Sellers
- Division of Cancer Prevention and Control, H. Lee Moffitt Cancer Centre, 12902 Magnolia Drive, Tampa, FL, USA
| | - Hui-Yi Lin
- Division of Cancer Prevention and Control, H. Lee Moffitt Cancer Centre, 12902 Magnolia Drive, Tampa, FL, USA
| | | | - Craig Teerlink
- Division of Genetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Heiko Muller
- Division of Clinical Epidemiology and Aging Research and
| | | | - Norihiko Tsuchiya
- Department of Urology,Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Shintaro Narita
- Department of Urology,Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
| | - Guang-Wen Cao
- Department of Epidemiology, Second Military Medical University, Shanghai, China
| | - Chavdar Slavov
- Department of Urology and Alexandrovska University Hospital,Medical University of Sofia, Sofia, Bulgaria
| | - Vanio Mitev
- Molecular Medicine Centre, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, 2 Zdrave St, Sofia 1431, Bulgaria
| | | | | | | | | | - Stephen Chanock
- Core Genotyping Facility, SAIC-Frederick, Inc., National Cancer Institute, NIH, Gaithersburg, MD, USA
| | - Henrik Gronberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm SE-171 77, Sweden
| | - Christopher A. Haiman
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Centre, Los Angeles, CA, USA
| | - Peter Kraft
- Program in Molecular and Genetic Epidemiology, Department of Epidemiology and
| | - Douglas F. Easton
- Strangeways Laboratory, Centre for Cancer Genetic Epidemiology, Worts Causeway, Cambridge CB1 8RN, UK
| | - Rosalind A. Eeles
- The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
- Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK
| |
Collapse
|
12
|
Salonen AJ, Taari K, Tammela TL. Reply from Authors re: Nicolas Mottet. Intermittent Androgen Deprivation in Prostate Cancer: Is Everything So Clear? Eur Urol 2013;63:121–2. Eur Urol 2013. [DOI: 10.1016/j.eururo.2012.08.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
13
|
Pöyhönen A, Häkkinen JT, Koskimäki J, Hakama M, Tammela TL, Auvinen A. Empirical evaluation of grouping of lower urinary tract symptoms: principal component analysis of Tampere Ageing Male Urological Study data. BJU Int 2012; 111:467-73. [DOI: 10.1111/j.1464-410x.2012.11593.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- Antti Pöyhönen
- Department of Urology; Tampere University Hospital and University of Tampere; Tampere; Finland
| | | | - Juha Koskimäki
- Department of Urology; Tampere University Hospital and University of Tampere; Tampere; Finland
| | - Matti Hakama
- School of Public Health; University of Tampere; Tampere; Finland
| | - Teuvo L.J. Tammela
- Department of Urology; Tampere University Hospital and University of Tampere; Tampere; Finland
| | - Anssi Auvinen
- School of Public Health; University of Tampere; Tampere; Finland
| |
Collapse
|
14
|
Kotsar A, Nieminen R, Isotalo T, Mikkonen J, Uurto I, Kellomäki M, Talja M, Moilanen E, Tammela TL. Preclinical Evaluation of New Indomethacin-Eluting Biodegradable Urethral Stent. J Endourol 2012; 26:387-92. [DOI: 10.1089/end.2011.0327] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022] Open
Affiliation(s)
- Andres Kotsar
- Department of Urology, Tampere University Hospital, Tampere, Finland
| | - Riina Nieminen
- Immunopharmacology Research Group, Medical School, University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Taina Isotalo
- Department of Surgery, Päijät-Hämeen Central Hospital, Lahti, Finland
| | - Joonas Mikkonen
- Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland
| | - Ilkka Uurto
- Department of Vascular Surgery, Tampere University Hospital, Tampere, Finland
| | - Minna Kellomäki
- Department of Biomedical Engineering, Tampere University of Technology, Tampere, Finland
| | - Martti Talja
- Department of Surgery, Päijät-Hämeen Central Hospital, Lahti, Finland
| | - Eeva Moilanen
- Immunopharmacology Research Group, Medical School, University of Tampere and Tampere University Hospital, Tampere, Finland
| | | |
Collapse
|
15
|
Lu L, Cancel-Tassin G, Valeri A, Cussenot O, Lange EM, Cooney KA, Farnham JM, Camp NJ, Cannon-Albright LA, Tammela TL, Schleutker J, Hoegel J, Herkommer K, Maier C, Vogel W, Wiklund F, Emanuelsson M, Grönberg H, Wiley KE, Isaacs SD, Walsh PC, Helfand BT, Kan D, Catalona WJ, Stanford JL, FitzGerald LM, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Thibodeau SN, McDonnell SK, Hebbring S, Schaid DJ, Whittemore AS, Oakley-Girvan I, Hsieh CL, Powell I, Bailey-Wilson JE, Carpten JD, Seminara D, Zheng SL, Xu J, Giles GG, Severi G, Hopper JL, English DR, Foulkes WD, Maehle L, Moller P, Badzioch MD, Edwards S, Guy M, Eeles R, Easton D, Isaacs WB. Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. Prostate 2012; 72:410-26. [PMID: 21748754 PMCID: PMC3568777 DOI: 10.1002/pros.21443] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2011] [Accepted: 05/25/2011] [Indexed: 01/30/2023]
Abstract
BACKGROUND In spite of intensive efforts, understanding of the genetic aspects of familial prostate cancer (PC) remains largely incomplete. In a previous microsatellite-based linkage scan of 1,233 PC families, we identified suggestive evidence for linkage (i.e., LOD ≥ 1.86) at 5q12, 15q11, 17q21, 22q12, and two loci on 8p, with additional regions implicated in subsets of families defined by age at diagnosis, disease aggressiveness, or number of affected members. METHODS In an attempt to replicate these findings and increase linkage resolution, we used the Illumina 6000 SNP linkage panel to perform a genome-wide linkage scan of an independent set of 762 multiplex PC families, collected by 11 International Consortium for Prostate Cancer Genetics (ICPCG) groups. RESULTS Of the regions identified previously, modest evidence of replication was observed only on the short arm of chromosome 8, where HLOD scores of 1.63 and 3.60 were observed in the complete set of families and families with young average age at diagnosis, respectively. The most significant linkage signals found in the complete set of families were observed across a broad, 37 cM interval on 4q13-25, with LOD scores ranging from 2.02 to 2.62, increasing to 4.50 in families with older average age at diagnosis. In families with multiple cases presenting with more aggressive disease, LOD scores over 3.0 were observed at 8q24 in the vicinity of previously identified common PC risk variants, as well as MYC, an important gene in PC biology. CONCLUSIONS These results will be useful in prioritizing future susceptibility gene discovery efforts in this common cancer.
Collapse
Affiliation(s)
- Lingyi Lu
- Data Coordinating Center for the ICPCG and Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA
| | - Geraldine Cancel-Tassin
- CeRePP ICPCG Group, Hopital Tenon, Assistance publique-Hopitaux de Paris, 75020 Paris, France
| | - Antoine Valeri
- CeRePP ICPCG Group, Hopital Tenon, Assistance publique-Hopitaux de Paris, 75020 Paris, France
| | - Olivier Cussenot
- CeRePP ICPCG Group, Hopital Tenon, Assistance publique-Hopitaux de Paris, 75020 Paris, France
| | - Ethan M. Lange
- University of Michigan ICPCG Group
- Department of Genetics, University of North Carolina, Chapel Hill, NC, USA
| | - Kathleen A. Cooney
- University of Michigan ICPCG Group
- Department of Medicine, University of Michigan, Ann Arbor, MI, USA
| | - James M. Farnham
- University of Utah ICPCG Group, Division of Genetic Epidemiology, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Nicola J. Camp
- University of Utah ICPCG Group, Division of Genetic Epidemiology, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Lisa A. Cannon-Albright
- University of Utah ICPCG Group, Division of Genetic Epidemiology, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Teuvo L.J. Tammela
- University of Tampere ICPCG Group, University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Johanna Schleutker
- University of Tampere ICPCG Group, University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Josef Hoegel
- University of Ulm ICPCG Group
- Institut fuer Humangenetik, Universitaet Ulm, Germany
| | - Kathleen Herkommer
- University of Ulm ICPCG Group
- Urologische Klinik, Universität Ulm, Germany
- Urologische Klinik rechts der Isar, Technische Universitaet Muenchen, Germany
| | - Christiane Maier
- University of Ulm ICPCG Group
- Institut fuer Humangenetik, Universitaet Ulm, Germany
| | - Walther Vogel
- University of Ulm ICPCG Group
- Institut fuer Humangenetik, Universitaet Ulm, Germany
| | - Fredrik Wiklund
- Karolinska Institute ICPCG Group
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Monica Emanuelsson
- Karolinska Institute ICPCG Group
- Oncologic Centre, Umeå University, Umeå, Sweden
| | - Henrik Grönberg
- Karolinska Institute ICPCG Group
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | - Kathleen E. Wiley
- Johns Hopkins University ICPCG Group and Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
| | - Sarah D. Isaacs
- Johns Hopkins University ICPCG Group and Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
| | - Patrick C. Walsh
- Johns Hopkins University ICPCG Group and Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
| | - Brian T. Helfand
- Northwestern University ICPCG group, Department of Urology, Northwestern University Chicago, IL USA
| | - Donghui Kan
- Northwestern University ICPCG group, Department of Urology, Northwestern University Chicago, IL USA
| | - William J. Catalona
- Northwestern University ICPCG group, Department of Urology, Northwestern University Chicago, IL USA
| | - Janet L. Stanford
- FHCRC ICPCG Group
- Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, WA, USA
| | - Liesel M. FitzGerald
- FHCRC ICPCG Group
- Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, WA, USA
| | - Bo Johanneson
- FHCRC ICPCG Group
- Cancer Genetics Branch, NHGRI, National Institutes of Health, Bethesda, MD, USA
| | - Kerry Deutsch
- FHCRC ICPCG Group
- Institute for Systems Biology, Seattle, WA, USA
| | - Laura McIntosh
- FHCRC ICPCG Group
- Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, WA, USA
| | - Elaine A. Ostrander
- FHCRC ICPCG Group
- Cancer Genetics Branch, NHGRI, National Institutes of Health, Bethesda, MD, USA
| | | | | | | | | | - Alice S. Whittemore
- BC/CA/HI ICPCG Group
- Department of Health Research and Policy, Stanford School of Medicine, CA, USA
- Stanford Comprehensive Cancer Center, Stanford School of Medicine, CA, USA
| | - Ingrid Oakley-Girvan
- BC/CA/HI ICPCG Group
- Stanford Comprehensive Cancer Center, Stanford School of Medicine, CA, USA
| | - Chih-Lin Hsieh
- BC/CA/HI ICPCG Group
- Department of Urology and Department of Biochemistry and Molecular Biology, University of Southern California, CA, USA
| | - Isaac Powell
- African American Hereditary Prostate Cancer ICPCG Group
- Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
| | - Joan E. Bailey-Wilson
- African American Hereditary Prostate Cancer ICPCG Group
- National Human Genome Research Institute, NIH, Bethesda, MD, USA
| | - John D. Carpten
- African American Hereditary Prostate Cancer ICPCG Group
- Translational Genomics Research Institute, Genetic Basis of Human Disease Research Division, Phoenix, AZ, USA
| | | | - S. Lilly Zheng
- Data Coordinating Center for the ICPCG and Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA
| | - Jianfeng Xu
- Data Coordinating Center for the ICPCG and Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA
| | - Graham G. Giles
- ACTANE Consortium ICPCG Group
- Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia
| | - Gianluca Severi
- ACTANE Consortium ICPCG Group
- Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia
| | - John L. Hopper
- ACTANE Consortium ICPCG Group
- Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health, The University of Melbourne, Melbourne, Australia
| | - Dallas R. English
- ACTANE Consortium ICPCG Group
- Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health, The University of Melbourne, Melbourne, Australia
| | - William D. Foulkes
- ACTANE Consortium ICPCG Group
- Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
| | - Lovise Maehle
- ACTANE Consortium ICPCG Group
- The Norwegian Radium Hospital, Oslo, Norway
| | - Pal Moller
- ACTANE Consortium ICPCG Group
- The Norwegian Radium Hospital, Oslo, Norway
| | - Michael D. Badzioch
- ACTANE Consortium ICPCG Group
- Division of Medical Genetics, University of Washington Medical Center, Seattle, WA, USA
| | - Steve Edwards
- ACTANE Consortium ICPCG Group
- Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
| | - Michelle Guy
- ACTANE Consortium ICPCG Group
- Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
| | - Ros Eeles
- ACTANE Consortium ICPCG Group
- Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
| | - Douglas Easton
- ACTANE Consortium ICPCG Group
- Cancer Research UK Genetic Epidemiology Unit, Cambridge, UK
| | - William B. Isaacs
- Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, WA, USA
| |
Collapse
|
16
|
Jalava SE, Latonen L, Scaravilli M, Waltering KK, Seppälä J, Lähdesmäki H, Tammela TL, Visakorpi T. Abstract A9: Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Cancer Res 2012. [DOI: 10.1158/1538-7445.prca2012-a9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The androgen receptor (AR) signaling pathway is central to the emergence of castration-resistant prostate cancer (CRPC). We set out to identify androgen-regulated microRNAs (miRNAs) that may contribute to the development of CRPC. We found miR-32 to be an androgen regulated miRNA which is differentially expressed in CRPC compared to benign prostate hyperplasia (BPH) according to microarray analyses. qRT-PCR analyses confirmed that miR-32 expression increases in CRPC compared to BPH, and that in untreated prostate cancer (PC) miR-32 expression is higher in tumors of stage pT3 compared to pT2. Transfection of pre-miR-32 to prostate cancer cell line LNCaP provided a significant growth advantage to the cells, and miR-32 was further demonstrated to reduce apoptosis. To identify target genes for miR-32, an mRNA microarray analysis was performed with LNCaP cells transfected with pre-miR-32. In this assay, B cell translocation gene 2 (BTG2) was identified as a novel putative target for miR-32. BTG2 was reduced both at mRNA and protein level in the cells transfected with pre-miR-32, and BTG2 was confirmed to be a miR-32 target by 3′-UTR-luciferase assay. Furthermore, BTG2 was able to partially rescue the growth advantage of miR-32 in LNCaP cells. Immunostainings of prostate cancer patient material showed a statistically significant (p < 0.0001) reduction of BTG2 protein in CRPCs compared to PC. The lack of BTG2 staining was also associated (p=0.0021) with a short progression-free time in patients who underwent prostatectomy and inversely correlated to miR-32 expression levels. In conclusion, we find that miR-32 is an androgen-regulated miRNA targeting BTG2 and overexpressed in CRPC. Thus, miR-32 is a potential marker for aggressive disease and is a putative drug target in PC.
Citation Format: Sanni E. Jalava, Leena Latonen, Mauro Scaravilli, Kati K. Waltering, Janne Seppälä, Harri Lähdesmäki, Teuvo L.J. Tammela, Tapio Visakorpi. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castrationresistant prostate cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Prostate Cancer Research; 2012 Feb 6-9; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(4 Suppl):Abstract nr A9.
Collapse
Affiliation(s)
- Sanni E. Jalava
- 1University of Tampere, Tampere, Finland, 2Tampere University of Technology, Tampere, Finland, 3Aalto University School of Science and Technology, Helsinki, Finland, 4University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Leena Latonen
- 1University of Tampere, Tampere, Finland, 2Tampere University of Technology, Tampere, Finland, 3Aalto University School of Science and Technology, Helsinki, Finland, 4University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Mauro Scaravilli
- 1University of Tampere, Tampere, Finland, 2Tampere University of Technology, Tampere, Finland, 3Aalto University School of Science and Technology, Helsinki, Finland, 4University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Kati K. Waltering
- 1University of Tampere, Tampere, Finland, 2Tampere University of Technology, Tampere, Finland, 3Aalto University School of Science and Technology, Helsinki, Finland, 4University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Janne Seppälä
- 1University of Tampere, Tampere, Finland, 2Tampere University of Technology, Tampere, Finland, 3Aalto University School of Science and Technology, Helsinki, Finland, 4University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Harri Lähdesmäki
- 1University of Tampere, Tampere, Finland, 2Tampere University of Technology, Tampere, Finland, 3Aalto University School of Science and Technology, Helsinki, Finland, 4University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Teuvo L.J. Tammela
- 1University of Tampere, Tampere, Finland, 2Tampere University of Technology, Tampere, Finland, 3Aalto University School of Science and Technology, Helsinki, Finland, 4University of Tampere and Tampere University Hospital, Tampere, Finland
| | - Tapio Visakorpi
- 1University of Tampere, Tampere, Finland, 2Tampere University of Technology, Tampere, Finland, 3Aalto University School of Science and Technology, Helsinki, Finland, 4University of Tampere and Tampere University Hospital, Tampere, Finland
| |
Collapse
|
17
|
Leinonen KA, Tammela TL, Saramäki OR, Visakorpi T. Abstract A28: Correlation of ERG expression with other genetic and expression abnormalities in prostate cancer. Cancer Res 2012. [DOI: 10.1158/1538-7445.prca2012-a28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Fusion between TMPRSS2 (transmembrane protease, serine 2) and ERG (v-ets erythroblastosis virus E26 oncogene like (avian)) (TMPRSS2:ERG) is the most commonly found genetic alteration in prostate cancer and is found in 35–50% of all cases. TMPRSS2 is induced by the androgen receptor (AR). Fusion with TMPRSS2 renders ERG androgen inducible, causing most of its overexpression in prostate cancer. Studies suggest that SPINK1 (serine peptidase inhibitor, Kazal type 1) expression is exclusive to TMPRSS2:ERG fusion negative tumors, PTEN (phosphatase and tensin homolog) and TP53 (tumor protein p53) deletions are enriched in fusion positive tumors, a small region in chromosome 3p14 (including three possible tumor suppressor genes, FOX1, RYBP and SHQ1) is specifically deleted in a subset of fusion positive tumors, and that AR expression is down regulated in fusion positive tumors. Correlation with EZH2 (enhancer of zeste homolog 2 (Drosophila)) and Ki-67 (antigen identified by monoclonal antibody Ki-67) expression has also been suggested.
To confirm these correlations we used fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) techniques in our sample material, which consisted of 330 prostatectomy samples and 150 locally recurrent castration resistant prostate cancers (CRPC).
About half of the prostatectomy (47%, 107/230) and CRPC (45%, 70/156) samples showed positive ERG staining and ERG positivity was significantly associated with longer progression-free survival (p=0.0001, Log rank test) compared to ERG negative cases. Positive SPINK1 expression was seen in 14% (34/243) of the prostatectomy samples and in 12% (17/138) of the CRPC tumors. SPINK1 was almost exclusively expressed in ERG negative tumors (in prostatectomies p<0.0001 and in CRPCs p=0.0132, Fisher's exact test). High AR staining was seen in 82% (206/252) of the prostatectomy samples and in 93% (127/136) of the CRPC tumors. In prostatectomy samples, AR expression was significantly associated with ERG positivity (p<0.0001, Fisher's exact test). Low PTEN expression was seen in 15% (42/282) of the prostatectomy samples and in 45% (55/122) of the CRPC tumors. In CRPC tumors, but not in prostatectomy samples, loss of PTEN expression was associated with ERG positivity (p=0.0035, Fisher's exact test). Low PTEN expression was significantly associated with shorter progression-free survival compared to PTEN positive tumors (p=0.0133, Log rank test). Deletion of TP53 was seen in 8% (19/237) of the prostatectomy samples and in 18% (25/140) of the CRPC tumors. Deletion of chromosome region 3p14 was seen in approximately 4% of both prostatectomy (8/229) and CRPC (5/118) samples. Neither of these deletions was associated with ERG positivity. Analysis of Ki-67 and EZH2 staining is ongoing.
SPINK1 was almost exclusively expressed in ERG negative samples, and the association was statistically significant in both the prostatectomy samples and the locally recurrent CRPC samples. PTEN loss of expression was associated with ERG positivity in the CRPC samples, but not in the prostatectomy samples, indicating that this late event occurs preferentially in ERG positive cases. High AR expression was statistically significantly associated with ERG positivity. Since there shouldn't be any ERG expression from TMPRSS2:ERG fusion gene without AR, the results are in line with the known regulatory mechanisms of TMPRSS2:ERG. Contrary to previous reports, the specific deletions of 3p14 or TP53 were not enriched in the ERG positive samples. TP53 deletion was more frequent in the advanced disease.
Citation Format: Katri A. Leinonen, Teuvo L.J. Tammela, Outi R. Saramäki, Tapio Visakorpi. Correlation of ERG expression with other genetic and expression abnormalities in prostate cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Prostate Cancer Research; 2012 Feb 6-9; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(4 Suppl):Abstract nr A28.
Collapse
Affiliation(s)
- Katri A. Leinonen
- 1University of Tampere, Tampere, Finland, 2Tampere University Hospital, Tampere, Finland
| | - Teuvo L.J. Tammela
- 1University of Tampere, Tampere, Finland, 2Tampere University Hospital, Tampere, Finland
- 1University of Tampere, Tampere, Finland, 2Tampere University Hospital, Tampere, Finland
| | - Outi R. Saramäki
- 1University of Tampere, Tampere, Finland, 2Tampere University Hospital, Tampere, Finland
| | - Tapio Visakorpi
- 1University of Tampere, Tampere, Finland, 2Tampere University Hospital, Tampere, Finland
| |
Collapse
|
18
|
Murtola TJ, Syvälä H, Pennanen P, Bläuer M, Solakivi T, Ylikomi T, Tammela TL. Comparative effects of high and low-dose simvastatin on prostate epithelial cells: The role of LDL. Eur J Pharmacol 2011; 673:96-100. [DOI: 10.1016/j.ejphar.2011.10.022] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2011] [Revised: 10/03/2011] [Accepted: 10/11/2011] [Indexed: 12/31/2022]
|
19
|
Tolonen TT, Kujala PM, Laurila M, Tirkkonen M, Ilvesaro J, Tuominen VJ, Tammela TL, Isola J. Routine dual-color immunostaining with a 3-antibody cocktail improves the detection of small cancers in prostate needle biopsies. Hum Pathol 2011; 42:1635-42. [DOI: 10.1016/j.humpath.2010.12.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2010] [Revised: 12/20/2010] [Accepted: 12/22/2010] [Indexed: 10/18/2022]
|
20
|
Murtola TJ, Tammela TL. Abstract A97: Risk of biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers. Cancer Prev Res (Phila) 2011. [DOI: 10.1158/1940-6207.prev-11-a97] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Previous studies have demonstrated that 5α-reductase inhibitors (5-ARIs) finasteride and dutasteride decrease overall prostate cancer risk, while the proportion of high risk tumors may be increased. We compared risk of biochemical recurrence and mortality after radical prostatectomy between users of 5-ARIs, alpha-blockers and medication non-users
Materials and Methods: A total of men 1,315 men who underwent radical prostatectomy at the Tampere University Hospital during 1995–2009 were included in the study cohort. Post-operatively, men were followed at six month intervals during the first postoperative year and yearly afterwards. Serum PSA was measured at each visit. Biochemical relapse was defined as PSA becoming detectable after the operation. Information on causes of death was obtained from the Finnish Cancer Registry. Data on medication purchases during 1995–2009 was obtained from national prescription database. Cox proportional regression was used to analyze hazard ratios (HRs) and 95% confidence intervals (95% CI) of biochemical relapse and death.
Results: A total of 117 men had used finasteride or dutasteride, while 372 had used tamsulosin or alfuzosin. During the follow-up 424 men had a biochemical relapse, while 124 died, of which 22 due to prostate cancer. The median follow-up time until biochemical relapse was 3.17 years and until death 5.08 years. Pathological T-stage and tumor Gleason score among users of either drug group did not significantly vary from non-users. However, 5-ARI and alpha-blocker users had more often local lymph node metastases and positive surgical margins. Prediagnostic PSA, Gleason grade, pathological T-stage and marginal positivity were all independent predictors of biochemical recurrence. Risk of biochemical relapse was comparable to non-users among 5–ARI users (HR 1.38; 95% CI 0.86–2.19), but elevated among alpha-blocker users (HR 1.71; 95% CI 1.31–2.25). However, this risk increase was only observed when alpha-blockers were being used after the surgery. Overall mortality and prostate cancer-specific mortality did not differ by medication usage.
Conclusions: Use of finasteride or dutasteride was not associated with prostate cancer grade in this population, although the users had more often local lymph node metastases and positive surgical margins. Nevertheless, the risk of biochemical recurrence and prostate cancer mortality were not affected by 5-ARI use. Our finding of increased risk of biochemical recurrence among alpha-blocker users likely reflects treatment of symptoms of aggressive prostate cancer with alpha-blockers.
Citation Information: Cancer Prev Res 2011;4(10 Suppl):A97.
Collapse
|
21
|
Pöyhönen A, Häkkinen JT, Koskimäki J, Hakama M, Tammela TL, Auvinen A. Prevalence of hesitancy in 30-80-year-old Finnish men: Tampere Ageing Male Urological Study (TAMUS). BJU Int 2011; 109:1360-4. [DOI: 10.1111/j.1464-410x.2011.10443.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
22
|
Tolonen TT, Tammela TL, Kujala PM, Tuominen VJ, Isola JJ, Visakorpi T. Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer. BJU Int 2011; 108:1430-8. [DOI: 10.1111/j.1464-410x.2011.10253.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
23
|
Pakkanen S, Kujala PM, Ha N, Matikainen MP, Schleutker J, Tammela TL. Clinical and histopathological characteristics of familial prostate cancer in Finland. BJU Int 2011; 109:557-63. [DOI: 10.1111/j.1464-410x.2011.10198.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
24
|
Vaughan CP, Johnson TM, Ala-Lipasti MA, Cartwright R, Tammela TL, Taari K, Auvinen A, Tikkinen KA. The Prevalence of Clinically Meaningful Overactive Bladder: Bother and Quality of Life Results from the Population-Based FINNO Study. Eur Urol 2011; 59:629-36. [DOI: 10.1016/j.eururo.2011.01.031] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2010] [Accepted: 01/14/2011] [Indexed: 10/18/2022]
|
25
|
Tikkinen KA, Cartwright R, Ala-Lipasti MA, Johnson TM, Tammela TL, Auvinen A. 1955 WHAT IS THE MOST BOTHERSOME LOWER URINARY TRACT SYMPTOM? INDIVIDUAL AND POPULATION LEVEL PERSPECTIVES. J Urol 2011. [DOI: 10.1016/j.juro.2011.02.2159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
26
|
Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernández Fernández E. Silodosin Therapy for Lower Urinary Tract Symptoms in Men with Suspected Benign Prostatic Hyperplasia: Results of an International, Randomized, Double-Blind, Placebo- and Active-Controlled Clinical Trial Performed in Europe. Eur Urol 2011; 59:342-52. [DOI: 10.1016/j.eururo.2010.10.046] [Citation(s) in RCA: 163] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2010] [Accepted: 10/31/2010] [Indexed: 10/18/2022]
|
27
|
Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, Tammela TL, Teloken C, Tindall D, Freedland SJ, Somerville MC, Wilson TH, Fowler I, Castro R, Rittmaster RS. The Effect of Dutasteride on the Usefulness of Prostate Specific Antigen for the Diagnosis of High Grade and Clinically Relevant Prostate Cancer in Men With a Previous Negative Biopsy: Results From the REDUCE Study. J Urol 2011; 185:126-31. [DOI: 10.1016/j.juro.2010.09.011] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2010] [Indexed: 10/18/2022]
Affiliation(s)
- Gerald L. Andriole
- Washington University School of Medicine in St. Louis, St. Louis, Missouri
| | | | - Otis W. Brawley
- American Cancer Society and Emory University, Atlanta, Georgia
| | - Leonard Gomella
- Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
| | | | | | - Curtis Pettaway
- The University of Texas M.D. Anderson Cancer Center, Houston, Texas
| | | | - Claudio Teloken
- UFCSPA - Federal University of Health Sciences and Santa Casa Hospital, Porto Alegre, Brazil
| | | | | | | | | | - Ivy Fowler
- GlaxoSmithKline, Research Triangle Park, North Carolina
| | - Ramiro Castro
- GlaxoSmithKline, Research Triangle Park, North Carolina
| | | | | |
Collapse
|
28
|
Carlsson SV, Holmberg E, Moss SM, Roobol MJ, Schröder FH, Tammela TL, Aus G, Auvinen AP, Hugosson J. No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU Int 2010; 107:1912-7. [DOI: 10.1111/j.1464-410x.2010.09712.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Kilpeläinen TP, Auvinen A, Määttänen L, Kujala P, Ruutu M, Stenman UH, Tammela TL. Results of the three rounds of the Finnish Prostate Cancer Screening Trial-The incidence of advanced cancer is decreased by screening. Int J Cancer 2010; 127:1699-705. [DOI: 10.1002/ijc.25368] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
30
|
Nickel JC, Tammela TL, Teloken C, Wilson TH, Fowler IL, Rittmaster RS. 797 DUTASTERIDE REDUCES PROSTATITIS SYMPTOMS COMPARED TO PLACEBO IN MEN ENROLLED IN THE REDUCE (REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS) STUDY. J Urol 2010. [DOI: 10.1016/j.juro.2010.02.1473] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
31
|
Smith MR, Saad F, Egerdie B, Sieber P, Tammela TL, Kupic A, Ke C, Leder BZ, Goessl C. 132 SARCOPENIA IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY (ADT) FOR PROSTATE CANCER: A PROSPECTIVE 3-YEAR STUDY. J Urol 2010. [DOI: 10.1016/j.juro.2010.02.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
32
|
Johnson TM, Tähtinen RM, Auvinen A, Tammela TL, Cartwright R, Tikkinen KA. 1763 ARE URINARY STORAGE SYMPTOMS RELATED WITH SMOKING? A POPULATION-BASED STUDY IN WOMEN. J Urol 2010. [DOI: 10.1016/j.juro.2010.02.1673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
33
|
Malmi H, Ruutu M, Määttänen L, Stenman UH, Juusela H, Tammela TL, Auvinen A. Why do men opt out of prostate-cancer screening? Attitudes and perception among participants and non-participants of a screening trial. BJU Int 2010; 106:472-7. [DOI: 10.1111/j.1464-410x.2010.09165.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
34
|
Kotsar A, Nieminen R, Isotalo T, Mikkonen J, Uurto I, Kellomäki M, Talja M, Moilanen E, Tammela TL. Biocompatibility of New Drug-eluting Biodegradable Urethral Stent Materials. Urology 2010; 75:229-34. [DOI: 10.1016/j.urology.2009.03.016] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2008] [Revised: 02/23/2009] [Accepted: 03/06/2009] [Indexed: 11/26/2022]
|
35
|
Kotsar A, Isotalo T, Uurto I, Mikkonen J, Martikainen P, Talja M, Kellomäki M, Salenius JP, Tammela TL. Urethralin situbiocompatibility of new drug-eluting biodegradable stents: an experimental study in the rabbit. BJU Int 2009; 103:1132-5. [DOI: 10.1111/j.1464-410x.2008.08203.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
36
|
Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL. Finnish Multicenter Study Comparing Intermittent to Continuous Androgen Deprivation for Advanced Prostate Cancer: Interim Analysis of Prognostic Markers Affecting Initial Response to Androgen Deprivation. J Urol 2008; 180:915-9; discussion 919-20. [DOI: 10.1016/j.juro.2008.05.009] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2007] [Indexed: 11/16/2022]
Affiliation(s)
- Arto J. Salonen
- Departments of Urology, Kuopio University Hospital, Kuopio, Pohjois-Karjala Central Hospital, Joensuu, Keski-Suomi Central Hospital, Jyväskylä, Helsinki University Hospital, Helsinki, and Tampere University Hospital and University of Tampere, Tampere, Finland
| | - Jouko Viitanen
- Departments of Urology, Kuopio University Hospital, Kuopio, Pohjois-Karjala Central Hospital, Joensuu, Keski-Suomi Central Hospital, Jyväskylä, Helsinki University Hospital, Helsinki, and Tampere University Hospital and University of Tampere, Tampere, Finland
| | - Seppo Lundstedt
- Departments of Urology, Kuopio University Hospital, Kuopio, Pohjois-Karjala Central Hospital, Joensuu, Keski-Suomi Central Hospital, Jyväskylä, Helsinki University Hospital, Helsinki, and Tampere University Hospital and University of Tampere, Tampere, Finland
| | - Martti Ala-Opas
- Departments of Urology, Kuopio University Hospital, Kuopio, Pohjois-Karjala Central Hospital, Joensuu, Keski-Suomi Central Hospital, Jyväskylä, Helsinki University Hospital, Helsinki, and Tampere University Hospital and University of Tampere, Tampere, Finland
| | - Kimmo Taari
- Departments of Urology, Kuopio University Hospital, Kuopio, Pohjois-Karjala Central Hospital, Joensuu, Keski-Suomi Central Hospital, Jyväskylä, Helsinki University Hospital, Helsinki, and Tampere University Hospital and University of Tampere, Tampere, Finland
| | - Teuvo L.J. Tammela
- Departments of Urology, Kuopio University Hospital, Kuopio, Pohjois-Karjala Central Hospital, Joensuu, Keski-Suomi Central Hospital, Jyväskylä, Helsinki University Hospital, Helsinki, and Tampere University Hospital and University of Tampere, Tampere, Finland
| | | |
Collapse
|
37
|
Vaarala MH, Mattila H, Ohtonen P, Tammela TL, Paavonen TK, Schleutker J. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. Int J Cancer 2008; 122:2511-6. [DOI: 10.1002/ijc.23425] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
38
|
Kotsar A, Isotalo T, Mikkonen J, Juuti H, Martikainen PM, Talja M, Kellomäki M, Törmälä P, Tammela TL. A New Biodegradable Braided Self-Expandable PLGA Prostatic Stent: An Experimental Study in the Rabbit. J Endourol 2008; 22:1065-9. [DOI: 10.1089/end.2007.0047] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Andres Kotsar
- Department of Urology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland
| | - Taina Isotalo
- Department of Surgery, Päijät-Häme Central Hospital, Lahti, Finland
| | - Joonas Mikkonen
- Institute of Biomaterials, Tampere University of Technology, Tampere, Finland
| | - Hanne Juuti
- Institute of Biomaterials, Tampere University of Technology, Tampere, Finland
| | | | - Martti Talja
- Department of Surgery, Päijät-Häme Central Hospital, Lahti, Finland
| | - Minna Kellomäki
- Institute of Biomaterials, Tampere University of Technology, Tampere, Finland
| | - Pertti Törmälä
- Institute of Biomaterials, Tampere University of Technology, Tampere, Finland
| | - Teuvo L.J. Tammela
- Department of Urology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland
| |
Collapse
|
39
|
Sairanen J, Hotakainen K, Tammela TL, Stenman UH, Ruutu M. Urinary Epidermal Growth Factor and Interleukin-6 Levels in Patients with Painful Bladder Syndrome/Interstitial Cystitis Treated with Cyclosporine or Pentosan Polysulfate Sodium. Urology 2008; 71:630-3. [DOI: 10.1016/j.urology.2007.11.055] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2007] [Revised: 10/23/2007] [Accepted: 11/12/2007] [Indexed: 10/22/2022]
|
40
|
Murtola TJ, Tammela TL, Määttänen L, Auvinen A. 1719: Statins and Prostate Cancer Among Men Participating in the Finnish Prostate Cancer Screening Trial. J Urol 2007. [DOI: 10.1016/s0022-5347(18)31907-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
41
|
Tikkinen KA, Tammela TL, Rissanen AM, Valpas A, Huhtala H, Auvinen A. 69: Prevalence of Overactive Bladder is Overestimated. J Urol 2007. [DOI: 10.1016/s0022-5347(18)30334-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
42
|
Murtola TJ, Tammela TL, Lahtela J, Auvinen A. 462: Antidiabetic Medication and Prostate Cancer Risk - A Population-Based Case-Control Study. J Urol 2007. [DOI: 10.1016/s0022-5347(18)30715-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
43
|
Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2007; 122:595-602. [DOI: 10.1002/ijc.23145] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
44
|
Murtola T, Tammela TL, Maattanen L, Auvinen A. Serum Lipid-Lowering Drugs and Prostate Cancer Risk - A Population Based Case-Control Study. Am J Epidemiol 2006. [DOI: 10.1093/aje/163.suppl_11.s113-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Pakkanen SK, Baffoe-Bonnie A, Koivisto P, Matikainen MP, Tammela TL, Ou L, Bailey-Wilson JE, Schleutker J. 240: Segregation Analysis of 1,546 Families with Prostate Cancer in Finland. J Urol 2006. [DOI: 10.1016/s0022-5347(18)32507-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
46
|
Laurila M, Tammela TL, Auvinen A, Isola J, Visakorpi T, Maattanen L, Ruutu M, Ala-Opas M, Mildh M, Martikainen P. 1471: Biological Aggressiveness of Prostate Cancer in the Finnish Screening Trial. J Urol 2006. [DOI: 10.1016/s0022-5347(18)33675-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
47
|
Matikainen MP, Seppälä EH, Mononen N, Ikonen T, Ellonen P, Saharinen J, Saarinen J, Autio V, Tammela TL, Schleutker J. 242: Profiling Multigenetic Variation in Androgen Pathway as a Risk Factor for Prostate Cancer. J Urol 2005. [DOI: 10.1016/s0022-5347(18)34507-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
48
|
Kallio JP, Mikkelsson J, Tammela TL, Karhunen PJ, Kellokumpu-Lehtinen P. 1759: Genetic Variation in Platelet Fibrinogen Receptor and Metastatic Potential of Renal Cell Carcinoma. J Urol 2004. [DOI: 10.1016/s0022-5347(18)38951-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace D, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ. Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program. J Urol 2002. [DOI: 10.1016/s0022-5347(05)64652-6] [Citation(s) in RCA: 175] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- William A. See
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - Manfred P. Wirth
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - David G. McLeod
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - Peter Iversen
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - Ira Klimberg
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - Donald Gleason
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - Gerald Chodak
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - James Montie
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - Chris Tyrrell
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - D.M.A. Wallace
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - Karl P.J. Delaere
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - Sigmund Vaage
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - Teuvo L.J. Tammela
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - Olavi Lukkarinen
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - Bo-Eric Persson
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - Kevin Carroll
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| | - Geert J.C.M. Kolvenbag
- From the Medical College of Wisconsin, Milwaukee, Wisconsin, Department of Urology, Technical University of Dresden, Dresden, Germany, Walter Reed Army Medical Center, Washington, D. C., Department of Urology, Rigshospitalet, Copenhagen, Denmark, Urology Center of Florida, Ocala, Florida, Advanced Clinical Therapeutics Inc., Tucson, Arizona, Prostate and Urology Health Center, Chicago, Illinois, Urology Section, University of Michigan Health System, Ann Arbor, Michigan, Clinical Trials Unit,
| |
Collapse
|
50
|
Koskimäki J, Hakama M, Huhtala H, Tammela TL. [Prevalence of erectile dysfunctions and coital frequency]. Duodecim 2002; 116:737-41. [PMID: 12078140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Affiliation(s)
- J Koskimäki
- TAYS:n kirurgian klinikka PL 2000, 33521 Tampere.
| | | | | | | |
Collapse
|